Anavex Life Sciences Corp (AVXL)

[sokol]

Perhaps this (below) may be a basis for performing calculations to estimate “super” or “exceptional performers”. Based on this, it may be that 80% of treated patients (those with the wild type gene) that actually completed the phase 2b/3 Anavex AD trial likely received some benefit from AVXL 2-73, but those with an exceptional response is apparently much lower than the 80% number of fully treated patients.

Based on this (referenced below) … out of the 21 patients for which whole exome and transcriptome sequences were obtained, two patients showed exceptional therapeutic response during the longitudinal study (148-week period) - rounded to 10% of the 21 had exceptional response. This is the analysis of the phase 2a AVXL 2-73 clinical trial and may be the best we can find for a basis for calculating super responders. This article points out that 2 out of the 21 had an exceptional response - 10% (rounded).

Of course, some other patients within the 80% number of treated patients in the most recent AVXL AD trial likely benefited to some extent - some clinically meaningful, but the 76 number for super responders is likely a wild guess.

See this: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167374/